Matches in SemOpenAlex for { <https://semopenalex.org/work/W1920830047> ?p ?o ?g. }
- W1920830047 endingPage "91" @default.
- W1920830047 startingPage "82" @default.
- W1920830047 abstract "To assess the efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes enrolled in the CANagliflozin cardioVascular Assessment Study (CANVAS) who were on an incretin mimetic [dipeptidyl peptidase-4 (DPP-4) inhibitor or glucagon-like peptide-1 (GLP-1) receptor agonist].CANVAS is a double-blind, placebo-controlled study that randomized participants to canagliflozin 100 or 300 mg or placebo added to routine therapy. The present post hoc analysis assessed the efficacy and safety of canagliflozin 100 and 300 mg compared with placebo in subsets of patients from CANVAS who were taking background DPP-4 inhibitors or GLP-1 receptor agonists with or without other antihyperglycaemic agents at week 18.Of the 4330 patients in CANVAS, 316 were taking DPP-4 inhibitors and 95 were taking GLP-1 receptor agonists. At 18 weeks, canagliflozin 100 and 300 mg provided larger placebo-subtracted reductions in glycated haemoglobin (HbA1c) in patients taking DPP-4 inhibitors [-0.56% (95% confidence interval [CI]: -0.77, -0.35), and -0.75% (95% CI: -0.95, -0.54), respectively] and GLP-1 receptor agonists [-1.00% (95% CI: -1.35, -0.65), and -1.06% (95% CI: -1.43, -0.69), respectively]. Body weight and blood pressure (BP) reductions were seen with canagliflozin versus placebo in both subsets. Higher incidences of genital mycotic infections and osmotic diuresis-related adverse events (AEs) were seen with canagliflozin compared with placebo. The incidence of hypoglycaemia was numerically higher with canagliflozin versus placebo; nearly all events occurred in patients on background insulin or insulin secretagogues.In patients on background incretin mimetics, canagliflozin improved HbA1c, body weight and BP, with an increased incidence of AEs related to SGLT2 inhibition." @default.
- W1920830047 created "2016-06-24" @default.
- W1920830047 creator A5004194306 @default.
- W1920830047 creator A5007025699 @default.
- W1920830047 creator A5011127007 @default.
- W1920830047 creator A5012973322 @default.
- W1920830047 creator A5027520502 @default.
- W1920830047 creator A5031542137 @default.
- W1920830047 creator A5032297044 @default.
- W1920830047 creator A5039432822 @default.
- W1920830047 creator A5040652845 @default.
- W1920830047 creator A5045497276 @default.
- W1920830047 creator A5053469409 @default.
- W1920830047 creator A5075162144 @default.
- W1920830047 creator A5083959015 @default.
- W1920830047 creator A5090468892 @default.
- W1920830047 date "2015-12-08" @default.
- W1920830047 modified "2023-09-24" @default.
- W1920830047 title "Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes" @default.
- W1920830047 cites W1574738033 @default.
- W1920830047 cites W1968145432 @default.
- W1920830047 cites W1982905493 @default.
- W1920830047 cites W1983269691 @default.
- W1920830047 cites W2031730303 @default.
- W1920830047 cites W2038270027 @default.
- W1920830047 cites W2045790951 @default.
- W1920830047 cites W2068171948 @default.
- W1920830047 cites W2074989651 @default.
- W1920830047 cites W2077038286 @default.
- W1920830047 cites W2108472697 @default.
- W1920830047 cites W2114250030 @default.
- W1920830047 cites W2120919346 @default.
- W1920830047 cites W2130570549 @default.
- W1920830047 cites W2141800817 @default.
- W1920830047 cites W2160088494 @default.
- W1920830047 cites W2166823746 @default.
- W1920830047 cites W2167984652 @default.
- W1920830047 cites W2168926920 @default.
- W1920830047 doi "https://doi.org/10.1111/dom.12589" @default.
- W1920830047 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26450639" @default.
- W1920830047 hasPublicationYear "2015" @default.
- W1920830047 type Work @default.
- W1920830047 sameAs 1920830047 @default.
- W1920830047 citedByCount "73" @default.
- W1920830047 countsByYear W19208300472016 @default.
- W1920830047 countsByYear W19208300472017 @default.
- W1920830047 countsByYear W19208300472018 @default.
- W1920830047 countsByYear W19208300472019 @default.
- W1920830047 countsByYear W19208300472020 @default.
- W1920830047 countsByYear W19208300472021 @default.
- W1920830047 countsByYear W19208300472022 @default.
- W1920830047 countsByYear W19208300472023 @default.
- W1920830047 crossrefType "journal-article" @default.
- W1920830047 hasAuthorship W1920830047A5004194306 @default.
- W1920830047 hasAuthorship W1920830047A5007025699 @default.
- W1920830047 hasAuthorship W1920830047A5011127007 @default.
- W1920830047 hasAuthorship W1920830047A5012973322 @default.
- W1920830047 hasAuthorship W1920830047A5027520502 @default.
- W1920830047 hasAuthorship W1920830047A5031542137 @default.
- W1920830047 hasAuthorship W1920830047A5032297044 @default.
- W1920830047 hasAuthorship W1920830047A5039432822 @default.
- W1920830047 hasAuthorship W1920830047A5040652845 @default.
- W1920830047 hasAuthorship W1920830047A5045497276 @default.
- W1920830047 hasAuthorship W1920830047A5053469409 @default.
- W1920830047 hasAuthorship W1920830047A5075162144 @default.
- W1920830047 hasAuthorship W1920830047A5083959015 @default.
- W1920830047 hasAuthorship W1920830047A5090468892 @default.
- W1920830047 hasConcept C126322002 @default.
- W1920830047 hasConcept C126894567 @default.
- W1920830047 hasConcept C134018914 @default.
- W1920830047 hasConcept C142724271 @default.
- W1920830047 hasConcept C156490143 @default.
- W1920830047 hasConcept C170493617 @default.
- W1920830047 hasConcept C185280430 @default.
- W1920830047 hasConcept C197934379 @default.
- W1920830047 hasConcept C204787440 @default.
- W1920830047 hasConcept C27081682 @default.
- W1920830047 hasConcept C2777180221 @default.
- W1920830047 hasConcept C2777451236 @default.
- W1920830047 hasConcept C2778881409 @default.
- W1920830047 hasConcept C2778938600 @default.
- W1920830047 hasConcept C2779284873 @default.
- W1920830047 hasConcept C555293320 @default.
- W1920830047 hasConcept C71924100 @default.
- W1920830047 hasConcept C90924648 @default.
- W1920830047 hasConcept C98274493 @default.
- W1920830047 hasConceptScore W1920830047C126322002 @default.
- W1920830047 hasConceptScore W1920830047C126894567 @default.
- W1920830047 hasConceptScore W1920830047C134018914 @default.
- W1920830047 hasConceptScore W1920830047C142724271 @default.
- W1920830047 hasConceptScore W1920830047C156490143 @default.
- W1920830047 hasConceptScore W1920830047C170493617 @default.
- W1920830047 hasConceptScore W1920830047C185280430 @default.
- W1920830047 hasConceptScore W1920830047C197934379 @default.
- W1920830047 hasConceptScore W1920830047C204787440 @default.
- W1920830047 hasConceptScore W1920830047C27081682 @default.
- W1920830047 hasConceptScore W1920830047C2777180221 @default.
- W1920830047 hasConceptScore W1920830047C2777451236 @default.